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Introduction
The World Health Organisation defines myocarditis as an 
inflammatory disease of the myocardium diagnosed by 
established histological, immunological and immunohisto-
chemical criteria [1]. Myocardial involvement in presumed 
systemic viral infection is the most common aetiology, 
although it can result from a wide spectrum of infectious 
pathogens and non-infectious causes including systemic 
inflammatory conditions and toxins [2, 3].
Clinical presentation is often non-specific and hetero-
geneous, ranging from symptoms of chest pain, dyspnoea, 
fatigue or palpitations to brady- and tachy-arrhythmias, 
cardiogenic shock and sudden death [2]. Peripheral mark-
ers of inflammation (e.g. c-reactive protein) and myocardial 
injury (e.g. troponin) lack sensitivity and specificity, and 
viral serology is unhelpful [4–6]. Invasive endomyocardial 
biopsy (EMB) is recommended in specific scenarios, such 
as “New-onset heart failure of 2 weeks duration associated 
with a normal-sized or dilated left ventricle and hemody-
namic compromise (IB)” and “New-onset heart failure of 
2 weeks to 3 months duration associated with a dilated 
left ventricle and new ventricular arrhythmias, second- 
or third-degree heart block, or failure to respond to usual 
care within 1 to 2 weeks (1B)”, [7] however, it is associ-
ated with a risk of complications (1–2%) and due to sam-
pling error, transiency of myocardial injury and variation 
in histology interpretation, it also lacks accuracy [2, 8–12]. 
In most centres it is rarely performed. As a result of these 
factors, the diagnosis of myocarditis is challenging, and has 
traditionally been made after other cardiac diseases have 
been excluded [2].
Over the past decade, cardiac magnetic resonance 
(CMR) has changed this paradigm. The unique abil-
ity of multiparametric CMR to characterise myocardial 
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tissue, and thus potentially detect the myocardial oedema, 
increased blood flow and capillary leakage, necrosis and 
subsequent fibrosis that occurs in myocarditis, coupled with 
the ability of CMR to detect subtle regional or global con-
tractile dysfunction, means that CMR is now often able to 
provide a positive diagnosis of myocarditis. Indeed, CMR 
has provided pathophysiological insight into the nature of 
the myocardial injury in myocarditis.
This review will describe the diagnostic utility of CMR 
parameters across a range of myocarditic aetiologies. In this 
context, it is important to recognise that the evaluation of 
CMR, or indeed any diagnostic test, in myocarditis is lim-
ited by the lack of a good reference standard. Histological 
validation is challenging and imperfect, as described. As a 
result, many studies use a clinical diagnosis of myocarditis 
as the reference, however this is inherently limited. In addi-
tion, heterogeneous study designs and patient populations 
(e.g. acute versus chronic myocardial inflammation, defi-
nition of control groups), and the nature of CMR (differ-
ing magnetic field strengths, imaging sequences, measured 
parameters) makes comparisons between studies difficult.
Idiopathic (presumed viral) myocarditis
In North America and Europe, myocardial involvement in 
presumed systemic viral infection remains the most com-
mon aetiology of myocarditis [2, 13–18].
T2 weighted imaging
T2 relaxation is directly proportional to tissue water con-
tent, and T2 weighted (T2w) imaging has been proposed to 
detect myocardial oedema [3, 19, 20].
Table  1 summarises studies that have evaluated the 
diagnostic performance of T2w imaging, including the 
sequences employed, the populations studied and the refer-
ence standards [21–35]. Most studies analyse T2w images 
using an oedema ratio (ER), defined as the ratio of myo-
cardial to skeletal muscle signal intensity (SI), with val-
ues above a set value considered pathological. However, 
the threshold varies across studies (1.8–2.2), is usually 
determined retrospectively and the technique is hampered 
by potential coexistence of myositis and a lack of skeletal 
muscle in the field of view [21, 35]. A minority of stud-
ies have used qualitative assessment, although a lack of 
‘healthy’ myocardium for comparison in the context of 
global myocarditis is a limitation [35].
The pooled weighted sensitivity, specificity and diagnos-
tic accuracy of T2w for diagnosing acute myocarditis are 
63, 76 and 68% respectively.
In the largest study (104 patients), in which a clini-
cal diagnosis of myocarditis was used as the reference 
standard, Radunski et  al. reported a modest diagnostic 
accuracy (70%) [31]. Median interval between symptom 
onset and scan was 2 weeks, however the interquartile 
range was up to 7 weeks, by which time patients may have 
been in the convalescent stage. Indeed, the effect of delayed 
scan timing on T2w imaging sensitivity was investigated 
by Monney et al [36] and Hinojar et al [34], who found a 
higher prevalence of abnormal signal on T2w images when 
scanning within 2 weeks of symptom onset (81 and 56% 
respectively) compared to scanning performed later (11% at 
39 days [36] and 12% at 6 months [34]). Other studies com-
paring acute and convalescent imaging have also shown 
that high T2 signal is a transient feature of inflammatory 
response [36–40]. In addition, abnormalities detectable on 
T2w imaging appear to vary according to clinical presenta-
tion, with a higher prevalence in the context of infarction-
like symptoms (81% sensitivity) and much lower in the set-
ting of heart failure or arrhythmias (sensitivity 28 and 27% 
respectively) [41].
Early gadolinium enhancement
Early gadolinium enhancement  (EGE) exploits the phe-
nomenon of regional vasodilatation, increased blood flow 
and capillary leakage present in an inflammatory process 
which results in increased contrast retention in the early 
washout period [3].
Table 2 summarises studies that have evaluated the diag-
nostic performance of EGE imaging [3, 21–27, 29, 31–33, 
35, 42]. Analysis of EGE images is performed using Myo-
cardial Signal Enhancement, defined as myocardial SI 
post-contrast minus myocardial SI pre- contrast divided 
by myocardial SI pre- contrast, with values above 45–56% 
considered pathological [21, 29, 31], or more commonly, 
the global relative enhancement (gRE),[42] which is calcu-
lated as myocardial signal enhancement divided by skeletal 
muscle signal enhancement. Most studies use a gRE value 
of 4.0 as the threshold between healthy and abnormal myo-
cardium [22–27, 32]. Such analyses have similar disadvan-
tages to the ER.
The pooled weighted sensitivity, specificity and diag-
nostic accuracy of EGE for diagnosing acute myocardi-
tis are 66, 70 and 67% respectively, with a wide range of 
diagnostic performances reported for both myocardial sig-
nal enhancement and gRE analysis techniques. Interest-
ingly, Bohnen et al. found no statistical difference in gRE 
between heart failure patients with histologically confirmed 
inflammation and those without [43].
Friedrich et  al [42, 44] found the pattern of signal 
enhancement was localised within first week but sub-
sequently became more diffuse. By day 14, gRE values 
stopped being significantly higher in the myocarditis group 
compared to the control group. Studies comparing EGE in 
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acute and convalescent phases show a significant drop in 
gRE, from 4.1–8.5 during acute presentation to 2.4–4.4 at 
follow up (performed 3–28 months later) [37–40].
Late gadolinium enhancement
Late gadolinium enhancement (LGE) was originally 
thought to demonstrate irreversible myocardial injury 
only, however several studies have demonstrated a tempo-
ral change in the extent of LGE in myocarditis, with LGE 
volume seen to decrease significantly over time (follow up 
scans performed between 1 and 18 months) [3, 36–38, 40, 
45]. Histological correlation has shown LGE is associated 
with active inflammation, with the extent of LGE corre-
sponding to the severity of the inflammatory histopatholog-
ical findings [45, 46]. It is likely that LGE in acute myocar-
ditis represents both reversible and irreversible myocardial 
injury, but in the chronic phase represents residual focal 
fibrosis. See Fig. 1a for a representative example.
Table 3 summarises studies that have evaluated the diag-
nostic performance of LGE imaging [22–27, 29–35, 45, 
47]. The pooled weighted sensitivity, specificity and diag-
nostic accuracy of LGE for diagnosing acute myocarditis 
are 65, 95 and 75% respectively. The prevalence of LGE 
varies considerably across studies (27–95%), likely reflect-
ing the heterogeneity of the populations studied and the 
timing of CMR [22–27, 29–36, 40, 45, 47–51].
While a number of studies have shown that LGE can 
involve any region of the LV (or the right ventricle), Mah-
rholdt et  al.[46] in seminal work, showed LGE is most 
commonly located in the lateral LV, typically originating 
from the epicardial quartile of the LV wall. Transmural 
lateral wall LGE, possibly reflecting very florid disease, 
is reported in a minority [22, 23, 26, 27, 30, 33, 36, 40, 
45, 47, 49–53]. The distribution of LGE may be associated 
with the infecting pathogen, with parvovirus B19 found 
to be association with sub-epicardial lateral wall LGE, 
whereas human herpes virus 6 is associated with mid wall 
septal LGE [45].
LGE imaging requires the presence of ‘normal’ myocar-
dium as a reference, thus may not be sensitive to diffuse 
disease [54].
Lake Louise criteria
In an effort to increase the diagnostic performance of CMR, 
the three tissue characterisation techniques discussed above 
(T2w imaging, EGE and LGE) were combined to form the 
Lake Louise Criteria (LLC). In the setting of clinically sus-
pected myocarditis, abnormal findings on two of the three 
techniques were determined to be consistent with myocar-
dial inflammation [3].
Table 4 summarises studies that have evaluated the diag-
nostic performance of the LLC [22, 23, 25–27, 31–33, 35]. 
The pooled weighted sensitivity, specificity and diagnostic 
accuracy of the LLC for diagnosing acute myocarditis are 
80, 87 and 83% respectively, and as such the LLC dem-
onstrate a better overall diagnostic performance than any 
of the individual CMR parameters. Similar to T2w imag-
ing, LLC appears to have better diagnostic performance in 
“infarct-like” presentation (sensitivity of 80%) compared to 
heart failure or arrhythmias (sensitivity 57 and 40% respec-
tively) [41].
Parametric mapping
In recent years, parametric mapping, which allows direct 
quantification of myocardial tissue magnetic parameters 
(primarily T1 and T2) has been increasingly applied in 
myocarditis. (Similar to T2, T1 relaxation times are sensi-
tive to changes in myocardial water content and have been 
proposed to detect myocardial oedema). As well as being 
associated with potentially less observer variability, less 
artefact and allowing global myocardial assessment, native 
T1 and T2 mapping offer the significant advantage of not 
requiring contrast agent administration. See Fig. 1b, c for 
representative examples.
Table 5 summarises the studies that have evaluated the 
diagnostic performance of T2 and T1 mapping. The pooled 
weighted sensitivity, specificity and diagnostic accuracy 
of T2 mapping for diagnosing acute myocarditis are 70, 
91 and 79% respectively [31, 35, 43, 51, 55]. The pooled 
weighted sensitivity, specificity and diagnostic accuracy of 
T1 mapping are 82, 91 and 86% [30–32, 34, 35]. Thus the 
diagnostic performance of T2 mapping is comparable to 
that of the LLC, while the performance of T1 mapping may 
be superior.
Luetkens et al. compared the diagnostic performance of 
CMR parameters in two studies, albeit in relatively small 
populations (24 and 34 patients with myocarditis respec-
tively), and demonstrated similar findings. In the first 
study, which did not include T2 mapping [32], native T1 
mapping was associated with the highest diagnostic perfor-
mance (area under the curve, AUC 0.94), followed by LGE 
(AUC 0.9), LLC (AUC 0.86), ER (AUC 0.79) and gRE 
(AUC 0.63). In the second study, which included T2 map-
ping,[35], the performance of native T1 mapping (AUC 
0.92–0.95) and T2 mapping (AUC 0.92) was very similar. 
Combining T1 mapping with LGE (diagnostic accuracy 
91–96%) [30, 32, 34, 35] or T2 mapping and LGE (diag-
nostic accuracy 96%) [35] may improve diagnostic perfor-
mance further.
Nevertheless, there are a number of areas which require 
further investigation. Only one study has compared T1 
and T2 mapping with histological findings in myocarditis. 
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Relaxation time thresholds for diagnosing myocarditis have 
generally been determined retrospectively. T1 relaxation 
time diagnostic thresholds vary considerably between stud-
ies (852–1074 ms at 1.5 T). T2 relaxation time diagnostic 
thresholds are generally much more consistent (approxi-
mately 60  ms), however they overlap considerably with 
published normal ranges (up to 65 ms) [51, 56–66]. A pro-
spective, multicentre, multivendor trial with predetermined 
diagnostic thresholds is required to determine the clinical 
diagnostic utility of mapping with quantitative analysis 
before this technique can enter clinical practice.
Other noteworthy findings include those of Hinojar et al. 
who showed elevated T1 values (compared to healthy con-
trols) persisted for up to 4–8 months post initial presenta-
tion [34]. Bohnen et  al. found no difference in T1 values 
in patients with heart failure and histologically confirmed 
inflammation compared to patients with heart failure and 
no evidence of inflammation on histology [43]. This may 
reflect the fact that native T1 is determined by a number of 
factors other than inflammation (e.g. fibrosis).
Only three studies have examined the diagnostic utility 
of ECV in myocarditis, with varying results (Table 5) [31, 
32, 35].
Acute cardiac allograft rejection
Acute cardiac allograft rejection (ACAR) is a leading 
cause of death in the first year post heart transplant, how-
ever clinical features are unreliable. Routine screening is 
therefore performed in order to detect ACAR and hence 
augment immunosuppressive therapy, at an earlier stage, 
with the aim of preventing progression to more severe 
disease [67, 68]. Histological analysis of myocardial 
tissue obtained at EMB remains the gold standard for 
ACAR surveillance however it is associated with a num-
ber of limitations. CMR is a potentially attractive screen-
ing modality.
In one of the largest human studies, which included 68 
patients undergoing 123 CMR scans, T2 relaxation time 
was significantly higher in grade 2 ACAR (57 ± 5 ms) com-
pared with grade 0 or 1 (50 ± 5 ms and 51 ± 8 ms, respec-
tively); and in grade 3 (65 ± 8 ms) compared with grade 2 
[69]. A T2 relaxation time of ≥56  ms, determined retro-
spectively, had a high NPV (97%) for detecting significant 
ACAR (≥grade 2). More recently in a study of approxi-
mately 50 patients undergoing 68 CMR scans, Usman 
et al. found myocardial T2 was significantly higher in the 
ACAR group (including 4 cases of >grade 2R ACAR, two 
cases of antibody-mediated rejection and two cases where 
ACAR treatment was started on the basis of high clinical 
suspicion alone) compared to the non-ACAR group [70]. A 
T2 of 56.4 ms yielded a sensitivity and specificity of 86.5 
and 94.6% respectively. However, both studies specifically 
selected patients who were known to have/suspected of 
having ACAR. Furthermore, patients were a scanned at a 
substantial time post-transplant (Marie et al. up to 6 years, 
Usman et  al. up to 2 years), thus missing the window in 
which early detection of ACAR is thought to be most use-
ful, indeed the benefit of routine screening later than one 
year post-transplant is subject to debate.
In a study of 22 patients undergoing 88 CMR scans over 
the first 5 months post-transplant, Miller et al. found myo-
cardial T1 and T2 were not significantly higher in grade 2R 
ACAR compared to grades 0R-1R [71]. However the study 
did demonstrate significant improvements in markers of 
LV structure and contractility, native T1, T2 and ECV and 
microvascular function over the period studied, providing 
Fig. 1  Patient with acute viral myocarditis. a Late enhancement 
imaging. Epicardial and mid-wall late enhancement (green arrows) in 
mid anterolateral and apical lateral segments. b T1 mapping, MOLLI 
sequence. Elevated T1 values in mid-wall and epicardial portion of 
basal—mid anterolateral and apical lateral segments (green arrows; 
T1 values in anterolateral wall: 1152  ms, T1 values in basal infer-
oseptum: 1031 ms). c T2 mapping, T2-prepared SFFP sequence. Ele-
vated T2 values in epicardial portion of mid anterolateral and apical 
lateral segments (green arrows; T2 values in mid anterolateral seg-
ment: 66 ms, T2 values in basal inferoseptum: 47 ms)
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insight into the myocardial injury associated with trans-
plantation, and its recovery.
It may be that CMR parameters become more useful 
for detecting ACAR as time from transplantation increases 
and the transplant-related myocardial injury subsides. The 
paradox however is that while non-invasive approaches to 
ACAR surveillance may become more discriminatory as 
time from transplantation increases, the benefit of the early 
detection of ACAR diminishes [71].
Sarcoidosis
Sarcoidosis is a multi-organ systemic inflammatory disor-
der characterized by the formation of non-caseating granu-
lomas [72]. Autopsy studies suggest cardiac sarcoidosis is 
a major cause for sarcoid-related mortality, however pre-
mortem diagnosis of cardiac sarcoid is challenging [72, 
73]. Endomyocardial biopsy and clinical diagnostic criteria 
[74] are limited [75].
Smedema et al. [76] found LGE in all patients (n = 12) 
meeting clinical criteria for cardiac sarcoid, and in a further 
17% who did not meet the criteria. Patel et al. [77] showed 
CMR identified twice as many patients (n = 21) with evi-
dence of myocardial involvement as clinical evaluation, 
which included 12-lead ECG and at last one non-CMR car-
diac investigation (echocardiography, radionuclide scintig-
raphy or cardiac catheterisation).
Regional and mural LGE distribution in cardiac sarcoid 
is markedly heterogeneous. LGE has been demonstrated 
in all LV and RV regions, albeit with some predilection 
to basal septal regions [76–80]. Subendocardial, mid wall, 
epicardial and transmural patterns have been described 
[76–80]. Using T2 mapping, Crouser et al. [81] found sig-
nificantly higher myocardial T2 values amongst 50 consec-
utive patients investigated for cardiac sarcoid compared to 
healthy controls. T2 cut off of 59 ms achieved sensitivity of 
54% and specificity of 100%.
18F-fluoro-2-deoxyglucose positron emission tomog-
raphy (18F-FDG PET; a marker of active inflammation) 
studies have provided insight into the CMR findings [82, 
83]. T2w signal and LGE have been demonstrated to cor-
respond to regions taking up 18F-FDG, with reduced uptake 
following corticosteroids, indicating active inflammation. 
However, LGE is also found in regions without 18F-FDG 
uptake, indicating fibrotic lesions. Thus T2w signal may 
reflect active inflammation, whereas LGE may reflect either 
active inflammation or fibrosis.
The presence of LGE is associated with a higher rate of 
sudden cardiac death (SCD) and ventricular tachyarrhyth-
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Systemic lupus erythematous
Systemic lupus erythematous (SLE) is a multisystem 
inflammatory disorder [85].
Cardiovascular involvement represents a significant 
cause of morbidity and mortality [86]. SLE associ-
ated myocarditis was shown to shorten the survival and 
is more common amongst patients with higher disease 
activity [87]. There is also a discrepancy between the 
number of myocarditis cases detected on autopsy and 
clinical diagnoses, suggesting common subclinical car-
diac involvement [88, 89]. There is considerable inter-
est in the accurate detection of myocardial involvement 
in SLE, and other rheumatological conditions, as it may 
potentially guide therapy aimed at reducing adverse car-
diovascular outcomes.
A small study by Singh et  al. [90] showed that T2 
relaxation times were higher in six patients with active 
SLE compared to five with lower disease activity and five 
healthy controls (T2 values of 82, 64 and 65 ms respec-
tively). Similarly, Abdel-Aty et al. [88] showed that both 
ER and gRE were significantly higher in patients with 
active disease, both correlated to disease activity and ER 
significantly decreased with clinical improvement.
Mavrogeni et al. [89] compared a group of twenty-five 
patients with active SLE and suspected cardiac involve-
ment with fifty patients suspected of having viral myo-
carditis showing no statistical difference in ER and EGE, 
potentially suggesting similar myocardial pathological 
processes in both conditions.
Puntmann et al. [91] showed that T1 and ECV values 
were significantly higher among thirty-three SLE patients 
in clinical remission compared to twenty-one healthy 
controls (T1 1152 ± 46 vs. 1056 ± 27 ms, p < 0.001; ECV 
30 ± 6% versus 26 ± 5%, p = 0.007). A challenge for the 
CMR community is to decipher whether such findings 
represent active inflammation or chronic fibrosis, or 
indeed both. The authors did not perform T2 mapping, 
however, ER did not differ between groups, potentially 
suggesting the T1 and ECV findings may represent fibro-
sis. Conversely, Zhang et  al. [92] demonstrated higher 
T2 values in twenty-four SLE patients with low disease 
activity compared to twelve healthy controls (58.2 ± 5.6 
vs. 52.8 ± 4.4 ms), which the authors suggested may rep-
resent ongoing myocardial inflammation.
LGE may be less prevalent in SLE. Zhang et  al. [92] 
observed no late enhancement amongst twenty-four SLE 
patients while Mavrogeni et  al. [89] found significantly 
less LGE amongst patients with active SLE compared 
to viral myocarditis (LGE volume 3.5 ± 5.5 vs. 8 ± 4.4%, 
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Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease 
[93]. Cardiovascular involvement is common, manifesting 
as coronary artery disease, myocardial inflammation and 
fibrosis, and is responsible for 40–80% of premature deaths 
[94–97].
Kobayashi et  al. [98] examined eighteen RA patients 
without a previous history of cardiovascular conditions, 
finding LGE in almost 40% of patients, with a mostly 
non-ischaemic distribution. The presence of LGE was cor-
related to higher disease activity scores (DAS28 4.77 vs. 
3.44, p = 0.011).
Mavrogeni et al. [99] used T2w imaging, EGE and LGE 
to compare two groups of RA patients in remission: twenty 
with and twenty without recent onset cardiac symptoms. 
10% of patients with symptoms had evidence of myocardial 
infarction with a typical ischaemic LGE pattern and 65% 
displayed evidence of myocarditis as defined by LLC. Over 
three quarters of those diagnosed with myocarditis experi-
enced an RA relapse within 6 weeks, possibly suggesting 
more active disease.
Ntusi et al. [100] found LGE to be present in almost half 
of twenty-eight examined RA patients with a mostly non-
ischaemic, mid wall pattern. In addition, 5% of patients 
were diagnosed with silent myocardial infarction based on 
the presence of subendocardial LGE and confirmed by cor-
onary angiography. There was no difference in global ER 
between RA patients and controls, however, RA patients 
had more areas of elevated ER (ER > 1.9, median 10 vs. 
0% amongst controls) suggesting the presence of focal 
myocardial oedema. Finally, global T1 values and ECV 
were significantly higher in the RA group (T1 973 ± 27 
vs. 961 ± 18  ms, p = 0.03; ECV 30.3 ± 3.4 vs. 27.9 ± 2%, 
p < 0.001). Although, in keeping with the findings in SLE, 
it is not clear to what extent these findings represent active 
inflammation or fibrosis and the magnitude of the differ-
ence in global T1, whilst statistically significant, were 
small.
It is clear from these CMR studies that subclinical car-
diac involvement is common. CMR parameters have the 
potential to risk stratify and guide therapy in RA, although 
further work is required to define the nature of the CMR 
findings in RA and their accuracy and reproducibility in 
this population.
Systemic sclerosis
Systemic Sclerosis (SSC) is an autoimmune connective tis-
sue disorder characterised by multi-organ fibrosis [101]. 
Cardiac involvement in SSC is estimated at 15–35% [101] 
and includes myocardial fibrosis, myocarditis, dilated 
cardiomyopathy, premature coronary artery disease, con-
duction abnormalities, valvular and pericardial disease 
[102]. Myocardial pathologies are often subclinical with 
higher prevalence on autopsy studies [103]. Overt cardiac 
disease is associated with poor prognosis, with a reported 
70% mortality at 5 years [104].
A number of studies have evaluated LGE in SSC 
patients, demonstrating a prevalence of LGE of between 4 
and 66% [105–114]. LGE prevalence and distribution does 
not seem to differ between limited and diffuse cutaneous 
forms of SSC [105, 106, 108, 113]. Both non-ischaemic 
and ischaemic patterns of LGE are described [105–112] 
It is not clear whether the non-ischaemic LGE represents 
inflammation or fibrosis. Microvascular dysfunction is a 
prominent feature of SSC and diffuse myocardial ischae-
mia evident on perfusion imaging may be part of the patho-
physiological process [107, 113].
In a study by Hachulla et al. [106] fifty-two SSC patients 
without prior cardiac disease were assessed by multipara-
metric CMR. Qualitative T2w signal was increased in 12% 
of participants. Ntusi et al. [110] study found nineteen SCC 
patients to have a significantly greater extent of high gRE 
values compared to twenty healthy controls [110]. There 
was no difference between limited and diffuse cutaneous 
SSC [106, 110].
T1 mapping and ECV values were also shown to be 
higher in SSC patients without past cardiovascular involve-
ment. In previously mentioned study by Ntusi et al. [110], 
SSC participants had mean T1 values of 1007 ± 29  ms 
and ECV of 35.4 ± 4.8% compared to T1 of 958 ± 20  ms 
(p < 0.001) and ECV of 27.6 ± 2.5% (p < 0.001) amongst 
controls. Two further studies confirmed higher ECV in 
SSC patients compared to healthy controls: Barison et  al. 
[109] (30 SSC patients, ECV 30 ± 4% vs. 28 ± 4%, p = 0.03) 
and Thuny et al. [115] (33 SSC patients, median ECV 30%, 
range 28–31.9% vs. 26.8%, range 25.4–29.1%, p = 0.001).
Conclusions
By providing a ‘positive’ diagnostic test, CMR has changed 
the management of suspected viral myocarditis and has 
provided new insight into myocardial involvement in sys-
temic inflammatory conditions. Thus CMR has opened a 
window for potential therapeutic targets. Parametric map-
ping appears to offer advantages over more conventional 
CMR techniques. However, multicentre, multivendor clini-
cal trials are required to fully establish the clinical utility of 
CMR in myocarditis, and, in particular, quantitative map-
ping analysis.
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